ArticleTransplantation direct2025
A Randomized Double-blind Placebo-controlled Feasibility Study of IVIG Therapy in Lung Transplantation.
Article in Transplantation direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IVIG therapy may be clinically beneficial following lung transplantation (LTx), either by correcting hypogammaglobulinemia or by mitigating the humoral response to the lung allograft. However, the evidence base in LTx is limited. We aimed to recruit 40 LTx patients into a pilot placebo-controlled study of adding IVIG therapy to standard immunosuppression. The primary aim of the study was to provide feasibility data to inform the subsequent design of a definitive phase 2/3 randomized controlled trial. Methods: Stable patients were recruited between 3 and 6 mo post-LTx to receive 6 monthly infusions of either IVIG (0.4 g/kg) or placebo. Patients were followed for 12 mo. Primary study outcomes were related to feasibility; namely, the proportion of patients who (1) were screened to be eligible, (2) were eligible and enrolled, (3) lost to follow-up, and (4) received their allocated treatment. Although clinical data were collected, the study was not designed or powered to detect significant differences in clinical or adverse events. Results: Recruitment into the study was significantly impacted by the COVID pandemic. The final study cohort either received IVIG (n = 18) or placebo (n = 19). Four patients on IVIG did not receive the full complement of 6 study infusions because of infusion reactions. Otherwise, there was no significant difference in the safety profile between the 2 study arms. Four patients, all randomized to placebo, were unblinded because of clinical concerns and started on open-label IVIG. Serum IgG levels increased, and the incidence of hypogammaglobulinemia was lower in the IVIG-treated arm. Conclusions: The use of IVIG was relatively well tolerated in LTx recipients. The extracted clinical and safety data support consideration and the design of a definitive multicenter randomized controlled trial of IVIG in LTx. Clinical Trial Registration: Australian and New Zealand Clinical Trial Registry: ACTRN12618001394235.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.